Frequently Asked Questions
Dupixent and CTCL: Frequently Asked Questions
Quick answers to the questions people ask most often about Dupixent, cutaneous T cell lymphoma, MDL 3180, and what to expect from a free case review.
- No fee unless you recover
- 100% confidential
- Nationwide claims
- MDL 3180 · District of New Jersey
Common Questions, Plain Answers
- Does Dupixent cause cancer?
- That is not proven. Several studies and an FDA safety signal point to a possible association between Dupixent and cutaneous T cell lymphoma, but researchers caution the link is not established as causal. Investigations and litigation are ongoing.
- What cancers are involved?
- The litigation focuses on cutaneous T cell lymphoma (CTCL), including the subtypes mycosis fungoides and Sézary syndrome. Other T cell lymphomas may be considered later.
- Has Dupixent been recalled?
- No. As of 2026, Dupixent has not been recalled, and the U.S. label did not carry a CTCL cancer warning. The FDA listed CTCL as a potential signal and said it is evaluating the need for regulatory action.
- Who makes Dupixent?
- Dupixent (dupilumab) is developed and sold by Regeneron Pharmaceuticals and Sanofi (with Sanofi subsidiary Genzyme).
- Is this a class action?
- No. The cases are consolidated as MDL 3180 in New Jersey. Each plaintiff keeps an individual claim.
- How much does a case review cost?
- Reviews are free, and these cases are typically handled on a contingency fee basis, meaning attorney fees are owed only if there is a recovery. Confirm the specific terms in any agreement you sign.
- How long do I have to file?
- Deadlines vary by state, often a few years, and can start when the injury or its cause was or should have been discovered. Because deadlines can be missed, prompt review is important.
- What will I be asked during intake?
- Generally your Dupixent use (condition treated, approximate dates, duration), your diagnosis (type and date), and basic contact information.
Attorney advertising. General information only, not medical or legal advice. Prior results do not guarantee a similar outcome.